Skip to main content
. 2018 Jul 26;7(9):4217–4227. doi: 10.1002/cam4.1623

Figure 1.

Figure 1

Patient disposition in the study. In total, 140 of 149 patients enrolled in the study received cetuximab plus chemotherapy, among which 133 and 127 were evaluable using the EORTC QLQ‐C30 and DLQI questionnaires, respectively